In models of nonalcoholic steatohepatitis (NASH), GLP-1 analogs have been shown to attenuate hepatic inflammation by reducing M1 macrophage infiltration and inhibiting NF-κB activity, thereby lowering the expression of pro-inflammatory mediators such as IL-6, TNF-α, and iNOS (Yusta et al., 2015). Here, GLP1R is linked to metabolic dysfunction-associated steatohepatitis.